Amyloid plaques that accumulate in the brains of patients with Alzheimer's disease (AD) are primarily composed of aggregates of amyloid peptides that are derived from the amyloid precursor protein (APP). Overexpression of APP in cell cultures increases the formation of amyloidogenic peptides and causes neurodegeneration and cognitive dysfunction in transgenic mice. We now report that activation of prostaglandin E 2 (PGE 2 ) receptors increases cAMP formation and stimulates overexpression of APP mRNA and holoprotein in primary cultures of cortical astrocytes. Levels of glial fibrillary acidic protein were also increased by PGE 2 treatment, suggesting that these cultured astrocytes resemble reactive astrocytes found in vivo. The stimulation by PGE 2 of APP synthesis was mimicked or blocked by activators or inhibitors, respectively, of protein kinase A. Actinomycin D or cycloheximide also inhibited the increase in APP holoprotein stimulated by PGE 2 . Treatment of astrocytes with 8-Bromo-cAMP or forskolin for 24 hr also stimulated APP overexpression in cultured astrocytes. The immunosuppressants cyclosporin A and FK-506 inhibited the increase in APP mRNA and holoprotein levels caused by PGE 2 or by other treatments that elevated cellular cAMP levels; the inhibitory effect of FK-506 but not of cyclosporin A was attenuated by rapamycin. These results suggest that prostaglandins produced by brain injury or inflammation can activate APP transcription in astrocytes and that immunosuppressants may be used to prevent APP overexpression and possibly the pathophysiological processes underlying AD.
Amyloid plaques that accumulate in the brains of patients with Alzheimer's disease (AD) are primarily composed of aggregates of amyloid peptides that are derived from the amyloid precursor protein (APP). Overexpression of APP in cell cultures increases the formation of amyloidogenic peptides and causes neurodegeneration and cognitive dysfunction in transgenic mice. We now report that activation of prostaglandin E 2 (PGE 2 ) receptors increases cAMP formation and stimulates overexpression of APP mRNA and holoprotein in primary cultures of cortical astrocytes. Levels of glial fibrillary acidic protein were also increased by PGE 2 treatment, suggesting that these cultured astrocytes resemble reactive astrocytes found in vivo. The stimulation by PGE 2 of APP synthesis was mimicked or blocked by activators or inhibitors, respectively, of protein kinase A. Actinomycin D or cycloheximide also inhibited the increase in APP holoprotein stimulated by PGE 2 . Treatment of astrocytes with 8-Bromo-cAMP or forskolin for 24 hr also stimulated APP overexpression in cultured astrocytes. The immunosuppressants cyclosporin A and FK-506 inhibited the increase in APP mRNA and holoprotein levels caused by PGE 2 or by other treatments that elevated cellular cAMP levels; the inhibitory effect of FK-506 but not of cyclosporin A was attenuated by rapamycin. These results suggest that prostaglandins produced by brain injury or inflammation can activate APP transcription in astrocytes and that immunosuppressants may be used to prevent APP overexpression and possibly the pathophysiological processes underlying AD.
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Alzheimer's disease (AD) is characterized by extracellular deposits of amyloid plaques that are associated with dystrophic neurites, reactive astrocytes, and microglia (Alzheimer, 1907) . These plaques are primarily aggregates of the amyloid peptide (A␤) that is derived from an abundant cellular protein, the amyloid precursor protein (APP). Constitutive APP processing prevents the A␤ formation by cleaving the holoprotein within the A␤ domain to release the soluble N terminus of APP (APPS) into the extracellular space (Esch et al., 1990; Sisodia et al., 1990) . APPS secretion in human cells, brain slices, cultured neurons, or astrocytes is enhanced by activation of cell-surface receptors coupled to increased phosphatidylinositol hydrolysis, tyrosine phosphorylation, or protein kinase C activity (Nitsch et al., 1992; Lee et al., 1995; Slack et al., 1995; Ulus and Wurtman, 1997) . The drastic alterations in neurotransmitter levels and second messenger signaling created by neurodegeneration and synapse loss observed in AD may disrupt APP processing and promote A␤ accumulation.
Overexpression of APP appears to be associated with the neuropathological findings of AD. C ell cultures overexpressing APP increase the formation of amyloid fibrils and neurotoxic peptides (Yoshikawa et al., 1992) . Transgenic mice overexpressing the 751-amino acid APP isoform that contains the Kunitztype protease inhibitor (KPI) domain also show early amyloid deposits, neurite dystrophy, and memory deficits (Cordell, 1994) . Interestingly, transgenic mice overexpressing the human APP695 isoform that lacks the KPI domain do not show amyloid deposits but nevertheless do develop astrogliosis and age-related cognitive impairments (Hsiao et al., 1995) .
Reactive astrocytes with increased glial fibrillary acidic protein (GFAP) levels are associated with aging. GFAP levels are elevated in brain tissue and cerebrospinal fluid of patients with AD (Wallin et al., 1996) . Brain injury causes persistent and rapid elevations in APP immunoreactivity in GFAP-positive astrocytes (Siman et al., 1989; Banati et al., 1995) . Synapse loss in AD is also associated with increased numbers of GFAP-positive astrocytes (Brun et al., 1995) . Indeed, increased levels of the mRNA for KPI-containing APP in the frontal cortex have been attributed to the astrocytic response during neuronal damage (Golde et al., 1990) . Thus, the pathological cascade in AD may include APP synthesis by reactive astrocytes.
Cytosolic phospholipase A 2 , which releases arachidonic acid from cellular phospholipids, is elevated in AD brain and after global ischemia (Clemens et al., 1996; Stephenson et al., 1996) . The cyclooxygenation of arachidonic acid produces prostaglandins that in turn regulate neurotransmission as well as immune and inflammatory responses by activating receptors coupled to cAMP formation (Goetzl et al., 1995) . We now show that activation of PGE 2 receptors increases cAMP formation and stimulates the synthesis of APP mRNA and APP holoprotein.
Parts of this work have been published previously in abstract form (Lee et al., 1997a) .
MATERIALS AND METHODS
Astroc yte cultures. Dissociated astrocytes were cultured from cortices of postnatal day 1-2 rat pups as described previously (McC arthy and de Vellis, 1980) with minor modifications (Lee and Wurtman, 1997a) . In brief, cells from dissociated cortices were plated onto poly-L-lysinecoated 35 or 100 mm culture dishes (10 -25 cells/mm 2 ). The initial culture media, M EM (Life Technologies, Gaithersburg, MD) containing 10% horse serum (BioWhittaker, Walkersville, MD), were aspirated 2-5 hr after plating to remove unattached cells and debris and replaced with M EM containing 7.5% fetal bovine serum (FBS, BioWhittaker). Half the medium was replaced with M EM /7.5% FBS twice weekly. Astrocytes were kept at 37°C in a humidified 5%C O 2 /95% air incubator for 10 -14 d, by which time the cultures were confluent and could be used for experiments.
Pharmacolog ical reagents and treatments. The following drugs were stored and frozen at 10 Ϫ2 M stock concentrations: PGE 2 (C albiochem, La Jolla, CA); H-89 dihydrochloride and Sp-cAM P triethylamine (Research Biochemicals International, Natick, M A); actinomycin D, cycloheximide, okadaic acid, rapamycin, forskolin, and 8-Bromo-cAM P (8Br-cAM P) (from either C albiochem or Research Biochemicals); cyclosporin A (Alexis Biochemicals); F K-506 (Fujisawa Pharmaceuticals, Osaka, Japan). The frozen aliquots were thawed and diluted in serum-free M EM (37°C) to appropriate concentrations for incubation of cultured astrocytes. When drugs were dissolved in 95% ethanol, an equivalent volume of ethanol was also added to control samples. C ells were incubated for either 1 or 24 hr with 1.5 ml of media with or without drugs at 37°C in a 5% C O 2 /95% air incubator. E xperiments were conducted at least three times in duplicate dishes unless stated otherwise.
Northern blots. Total RNA was extracted from astrocytes grown on 100 mm dishes using TRI Reagent (Molecular Research C enter, C incinnati, OH) and procedures recommended by the manufacturer. In brief, the medium was aspirated and the cells were scraped in 1 ml of TRI Reagent. After incubation for 15 min at room temperature, 0.2 ml of chloroform was added, mixed vigorously, and stored for another 15 min at room temperature. After centrif ugation at 13,000 rpm for 15 min, 0.5 ml of isopropanol was added to the aqueous phase of the mixture to precipitate RNA. The RNA pellet collected by centrif ugation (12,000 ϫ g, 15 min at 4°C) was washed with 70% ethanol once and solubilized in an appropriate amount of Formazol (Molecular Research C enter). RNA samples (ϳ20 g) were denatured by heating for 15 min at 60°C before loading onto 1.2% agarose-formaldehyde gels for electrophoresis. RNA was blotted onto Hybond poly vinyl membranes by overnight capillary trans- Figure 1 . Effect of PGE 2 on cellular and secreted APP and on cAM P production in cultured astrocytes. A, Representative immunoblots show that 0.1, 1, 10, and 100 M PGE 2 treatment for 24 hr stimulated dose-dependent increases in cellular APP holoprotein. The levels of APP holoprotein as measured by mAb 22C11, antisera R37, or antisera R98 did not differ significantly. B, The graph represents the means and SEM of APP holoprotein levels stimulated by different concentrations of PGE 2 (*p Ͻ 0.05). Densitometric analysis of APP levels using mAb 22C11 (n ϭ 2), antiserum R37 (n ϭ 2), or antiserum R98 (n ϭ 1) were expressed as arbitrary values and normalized to the levels obtained from untreated, control cells. C, Representative immunoblots showing the levels of APP released into the media, as detected by mAb 22C11 or antiserum C8. Both immunoblots revealed increased amounts of secreted APP after PGE 2 treatment for 24 hr compared with control cells. Similar results were obtained from a subsequent experiment. D, Dose-dependent increases in cellular cAM P levels obtained by PGE 2 treatment of astrocytes. Graph represents means and SEM from a representative experiment performed on duplicate dishes (*p Ͻ 0.05).
fer and fixed onto the membranes by UV light illumination. Membranes were prehybridized with Amersham Rapid-hyb (Amersham, Arlington Heights, IL) buffer for 2 hr and labeled overnight with f ull-length human APP695 cDNA (gift of Dr. Rachael Neve, McLean Hospital, Harvard Medical School, Belmont, M A) or with a human glyceraldehyde-3-phosphate dehydrogenase probe (G3PDH; C lontech, C ambridge, UK) labeled with [ 32 P]dC TP using random-primed extension (Amersham Megaprime DNA labeling kit). Membranes were dried and exposed to Kodak x-ray film for 24 -48 hr with an Amersham enhancer sheet. The relative amounts of mRNA obtained by hybridization were estimated using densitometric analyses of autoradiographs. The levels of APP mRNA were normalized to the amounts of G3PDH mRNA and expressed as a ratio to the levels in untreated, control cells.
Western blots. C ell-associated APP was detected from cultured astrocytes grown on 35 mm dishes. The treatment media were aspirated, and astrocytes were scraped into 50 l of lysis buffer (60 mM Tris-HC l, 4% SDS, 20% glycerol, 1 mM dithiothreitol) and collected in Eppendorf tubes. The samples were boiled for 10 min to inhibit protease activity. The total amount of protein in each sample as estimated by the bicinchoninic acid (Sigma, St. L ouis, MO) assay was not altered by pharmacological treatments. Before gel electrophoresis, 1 l of 5% bromphenol blue solution was added to each sample.
To detect secreted APP, culture media was collected after drug treatments, and phenylmethylsulfonyl fluoride was added to a final concentration of 2 mM. The media samples were centrif uged at 13,000 rpm for 10 min to remove cell debris. The supernatant fluids were applied to Sephadex PD-10 desalting columns (Pharmacia, Piscataway, NJ) and eluted with distilled water. Column eluates were frozen and dried by vacuum centrif ugation. The lyophilized proteins were reconstituted in 25 l of water to which was added 25 l of 2ϫ Laemmli gel-loading buffer, and the mixture was boiled for 5 min.
The amount of medium or cell protein loaded for SDS-PAGE (10 -20%) (Bio-Rad, Hercules, CA) was normalized for the amount of protein per sample. Proteins (equivalent to ϳ100 g cell protein per lane) were separated by electrophoresis, electroblotted onto poly vinylidene difluoride membranes (Immobilon-P; Millipore, Bedford, M A), and blocked in Tris-buffered saline with 0.15% T ween 20 (TBST) containing 5% powdered milk for 30 min. After two ϫ 10 min rinses in TBST, the membranes were incubated in TBST containing an appropriate antibody. Monoclonal antibodies 22C11 and GFAP (both from Boehringer Mannheim, Indianapolis, I N) were used to detect the N terminus of APP and GFAP, respectively; antisera R37 and R98 (gifts of Dr. F. Kametani, Tokyo Institute of Psychiatry, Tokyo, Japan) were used to detected the C terminus and K PI motif of APP, respectively; and antiserum C8 (gift of Dr. D. Selkoe, Women's Hospital, Harvard Medical School, C ambridge, M A) was used to detect the C terminus of APP.
After an overnight incubation, membranes were rinsed in TBST before being treated for 1 hr with a peroxidase-linked secondary antibody. After several rinses in TBST, protein bands were visualized on Kodak X-AR films by an enhanced chemiluminescence method (Amersham). Optical densities of the protein bands were quantitated by laser scanning densitometry (L K B, Bromma, Sweden) and normalized to the densities of those bands generated under control conditions. cA MP assay. Levels of cyclic AM P were measured using an [8-3 H]-cAM P assay kit (Amersham TRK 432) in astrocytes grown on 35 mm dishes. In brief, the media were aspirated, and the cells were rinsed twice with 1 ml of ice-cold PBS, scraped in 0.8 ml of ice-cold ethanol, and sonicated. The cell suspension was kept at room temperature for 5 min and then centrif uged, and the supernatant fluid was dried in a rotary evaporator. After resuspension in 120 l of Tris/ EDTA buffer, two duplicate samples of 50 l each were mixed with the binding protein and a [8- 3 H] adenosine 3Ј, 5Ј-cyclic phosphate tracer and incubated at 2-4°C for 2 hr. A charcoal suspension (100 l) was added to the samples before centrif ugation, and 200 l of the supernatant fluid was removed for scintillation counting. The amount of cyclic AM P (picomoles per milligram of protein) was estimated by comparisons with known standards and normalized to the amounts of whole-cell protein as determined by the bicinchoninic acid assay (Sigma).
Data anal ysis. Measurements of cellular and secreted proteins or of mRNA in treatment groups were normalized against those of control groups prepared in parallel and loaded onto the same blot. ANOVA and t tests were used to evaluate differences between groups (significance level, p ϭ 0.05) using drug treatments as the independent variable. Data are presented as means Ϯ SE; n ϭ number of independent experiments. RESULTS PGE 2 coupled to cAMP production increases the expression of APP holoprotein and mRNA Treatment of astrocytes for 24 hr with 1, 10, or 100 M PGE 2 significantly increased the amounts of astrocytic APP holoprotein relative to those in untreated cells (all p Ͻ 0.05) (Fig. 1 A) . Similar increases in APP holoprotein (ϳ110 -130 kDa) were detected by monoclonal antibody (mAb) 22C11, antisera R37, or antisera R98 on Western blots (Fig. 1 B) . Treatment of astrocytes for 48 hr with 1, 10, or 100 M PGE 2 produced linear increases in cellular APP holoprotein that were 1.4 Ϯ 0.1-fold (n ϭ 3), 1.94 Ϯ 0.06-fold (n ϭ 5), and 2.34 Ϯ 0.07-fold (n ϭ 3), respectively, those in untreated, control cells (Fig. 1 B) . Treatment of astrocytes for 48 hr with 1, 10, or 100 M PGE 2 stimulated the expression of APP holoprotein to levels that were 1.4 Ϯ 0.12-fold (n ϭ 3), 1.7 Ϯ 0.05-fold (n ϭ 3), and 1.9 Ϯ 0.1-fold (n ϭ 3), respectively those in untreated cells (all p Ͻ 0.05).
APP secreted into the media (ϳ110 -130 kDa) was also increased by 24 hr treatment with 1, 10, or 100 M PGE 2 as assayed using mAb 22C11 or antiserum C8 (Fig. 1C) . Treatment with 1, 10, or 100 M PGE 2 also stimulated dose-dependent increases in cellular cAMP levels to 27-, 106-, and 227-fold those of untreated cells ( Fig. 1 D) ; 0.1 M PGE 2 did not stimulate cAMP production and did not significantly alter APP holoprotein or mRNA levels compared with those in untreated, control astrocytes ( p Ͼ 0.05). Actinomycin D and cycloheximide (both 2.5 M) inhibited the increase in APP holoprotein stimulated by PGE 2 (10 M) (Fig. 2) .
Protein kinase A and cAMP regulate APP expression
Treatment of astrocytes for 1 hr with membrane-permeant 8Br-cAMP (250 M) or with forskolin (10, 50, or 100 M) significantly increased cellular cAMP levels (Fig. 3A) and stimulated increases in APP mRNA (ϳ3.5 kb) and holoprotein after 24 hr treatments (Fig. 3B ). Astrocytes treated with 8Br-cAMP (250 M) expressed APP mRNA, APP holoprotein, and GFAP levels that were 1.6 Ϯ 0.1-fold (n ϭ 4), 2.1 Ϯ 0.2-fold (n ϭ 5), and 1.8 Ϯ 0.1-fold (n ϭ 5), respectively, those of untreated, control cells (all p Ͻ 0.05). Similarly, astrocytes treated with forskolin (50 M) expressed APP mRNA, APP holoprotein, and GFAP levels that were 1.8 Ϯ Figure 2 . Effect of actinomycin D (Act D) or cycloheximide (Cyclohex) on the increase in APP holoprotein stimulated by PGE 2 . Actinomycin D or cycloheximide (both 2.5 M) effectively inhibited the increase in APP holoprotein stimulated by PGE 2 (10 M) but had no significant effect on basal APP levels. Graph represents means and SEM from four independent experiments (*p Ͻ 0.05).
0.07-fold (n ϭ 3), 1.9 Ϯ 0.06-fold, (n ϭ 4) and 1.8 Ϯ 0.1-fold (n ϭ 4), respectively, those of untreated, control cells (all p Ͻ 0.05).
Activation of protein kinase A by 24 hr treatment with 50, 100, or 150 M Sp-cAM P triethylamine increased cellular levels of APP holoprotein to 1.6-, 1.9-, and 2.2-fold compared with those in untreated cells (Fig. 4 A) . Treatment with PGE 2 (10 M) alone resulted in astrocytic APP mRNA and holoprotein levels that were 1.7 Ϯ 0.1-fold (n ϭ 3) and 2.0 Ϯ 0.1-fold (n ϭ 3), respectively, those of untreated, control cells (all p Ͻ0.05). Cotreatment with both PGE 2 and the protein kinase A inhibitor H-89 (100 M) resulted in APP mRNA and holoprotein levels that were not significantly different from those of control cells ( p Ͼ 0.05) (Fig. 4 B) .
Immunosuppressants cyclosporin A and FK-506 inhibit APP synthesis stimulated by PGE 2 or cAMP elevations
The increases in astrocytic APP holoprotein and mRNA stimulated by 24 hr treatments with 50 M forskolin or 10 M PGE 2 , respectively, were significantly inhibited by co-treatment with either 50 M cyclosporin A or 50 M FK-506 (Fig. 5) . Increases in GFAP levels stimulated by 10 M PGE 2 were not altered by co-treatments with cyclosporin A or FK-506 (both 50 M). Also, neither cyclosporin A nor FK-506 modified the increase in cellular cAMP levels produced by 10 M PGE 2 (Fig. 6) . Treatment of astrocytes with either cyclosporin A or FK-506 (both 50 M) alone had no significant effect on basal APP holoprotein or on cAMP levels ( p Ͼ 0.05). The increase in astrocytic APP holoprotein stimulated by 24 hr treatment with 10 M PGE 2 were also significantly inhibited by co-treatment with either 1 M cyclosporin A or 0.1 M FK-506; the inhibitory effect of F K-506 but not of cyclosporin A was blocked by rapamycin (1 M) (Fig. 7) .
DISCUSSION
Our results show that PGE 2 stimulates APP synthesis in cultured astrocytes. Increases in APP mRNA and holoprotein were increased by astrocytes treated with 1, 10, or 100 M PGE 2 for 24 hr. The increase in APP holoprotein stimulated by PGE 2 was inhibited by actinomycin D or cycloheximide, indicating that this increase in APP is mediated by transcription or translation of the APP gene. APP holoprotein was also increased by prolonged treatment (i.e., 48 hr) of astrocytes with 1, 10, or 100 M PGE 2 ; however, shorter duration treatment (6 or 12 hr) with 10 M PGE 2 did not reliably increase APP synthesis. APP synthesis in astrocytes is probably mediated by the increases in cAMP production stimulated by PGE 2 treatment because dose-dependent increases in APP holoprotein were paralleled by concentrationdependent elevations in cAMP levels in astrocytes treated with 1, 10, or 100 M PGE 2 . Neither cAMP nor APP holoprotein levels were increased by 0.1 M PGE 2 . Furthermore, the stimulatory effect of PGE 2 on APP synthesis was mimicked by membranepermeant 8Br-cAMP (250 M) or by activating adenylate cyclase with forskolin (10, 50, or 100 M). Activation of cAMPdependent protein kinase (PKA) by Sp-cAMP triethylamine in the absence of PGE 2 was sufficient to stimulate increases in astrocytic APP holoprotein. Furthermore, inhibition of PKA by H-89 dihydrochloride blocked the stimulatory effect of PGE 2 on APP mRNA production. These data provide strong support for PKA in mediating the stimulatory effect of cAMP on APP synthesis.
Astrocytes and microglia express low levels of APP751/770 isoforms in the resting state but upregulate these KPI-containing APP isoforms after brain injury or neurodegeneration (Siman et al., 1989; Solá et al., 1993; Banati et al., 1995) . Furthermore, Figure 5 . Effect of the immunosuppressant cyclosporin A or F K-506 on APP synthesis caused by PGE 2 or forskolin treatment of cultured astrocytes. A, Increases in APP mRNA caused by PGE 2 (10 M) are inhibited by the immunosuppressant cyclosporin A (CsA) or F K-506 (both 50 M). Graph and SEM represent data collected from three independent experiments (*p Ͻ 0.05). B, Increases in APP holoprotein caused by forskolin (50 M) are inhibited by the immunosuppressant cyclosporin A (CsA) or F K-506 (both 50 M). Graph and SEM represent data collected from three independent experiments (*p Ͻ 0.05). C, Representative Northern and Western blots show that the increases in APP mRNA and APP holoprotein stimulated by PGE 2 (10 M), but not the increases in GFAP levels, were inhibited by cyclosporin A (CsA) or F K-506 (both 50 M).
KPI-containing APP mRNA is not usually expressed in the brain but is upregulated in frontal cortex of AD patients Golde et al., 1990) . Antiserum R98 (Kametani et al., 1993) revealed increases in K PI-containing APP isoforms after PGE 2 treatments. Increases in cellular APP holoprotein were also detected by antisera R37 directed at the C terminus of APP (Kametani et al., 1993) , indicating that the K PI-containing APP are full-length holoproteins harboring intact and potentially amyloidogenic A␤ peptides. Because mAb 22C11 recognizes the N termini of both APP and APP-like proteins (Weidemann et al., 1989; Slunt et al., 1994) , it is possible that PGE 2 treatment may also stimulate transcriptional regulation of other members of the APP gene family. To the extent that astrocytes proliferate and upregulate APP synthesis during aging and neuronal injury, these cells may contribute to the neuronal dysf unction and pathology of AD.
The APP promoter contains several sequences for regulatory elements that are responsive to cAM P signaling (Salbaum et al., 1988) . A consensus sequence for cAM P response elementbinding protein exists within the 3.7 kb region upstream from the APP transcription start site (Salbaum et al., 1988) . Although elevations in cAM P can activate AP-1 or AP-2 sites on the APP promoter, APP synthesis in NG108 -15 and HepG2 cells stimulated by dibutyryl cAMP appears not to depend on these sites (Bourbonniére et al., 1997; Shekarabi et al., 1997) . At least two other cAM P-responsive regions have been identified within the APP promoter of NG-108 cells (Bourbonniére et al., 1997) . It is not yet known whether these cis-acting regulators are functional for regulating APP synthesis in astrocytes or whether the induction of APP synthesis is mediated by trans-acting elements acting through the expression of other cAM P-responsive genes.
We found previously that the immunosuppressant cyclosporin A, at 1, 5, or 10 M, effectively inhibited APP synthesis in astrocytes treated with 8Br-cAM P. C yclosporin A at these concentrations had no significant effect on basal APP or GFAP levels, suggesting that cell death or cell viability was not altered by cyclosporin treatments (Lee et al., 1997b) . We did not determine in our previous study whether cyclosporin A would also inhibit APP synthesis mediated by receptor activation or whether other immunosuppressants such as F K-506 would be effective in regulating APP synthesis. We now show that cyclosporin A (1 or 50 M) or FK-506 (0.1 or 50 M) completely suppresses APP overexpression stimulated by PGE 2 or by forskolin. At 0.1 M concentrations, FK-506 but not cyclosporin A suppressed PGE 2 -stimulated APP overexpression, indicating that FK-506 is a more potent inhibitor than cyclosporin A. Lower concentrations of FK-506 (Ͻ 0.1 M) did not reliably suppress the increase in APP holoprotein stimulated by PGE 2 or 8Br-cAMP. Protein contents of astrocytes treated in the presence or absence of cyclosporin A (1 or 50 M) or FK-506 (0.1 or 50 M) assayed using the bichinchoninic assay did not differ, indicating that these immunosuppressants stimulated neither cell death nor cell proliferation. Toxicity produced by cyclosporin A or FK-506 might be expected to alter the production of second messengers (e.g., cAMP) in astrocytes. However, neither cyclosporin A nor FK-506 (both 50 M) affected basal cAMP levels in cultured astrocytes, and neither drug inhibited the increase in cAMP caused by PGE 2 . These results indicate that neither immunosuppressant was toxic, and that the inhibitory effect of cyclosporin A or FK-506 appears to lie downstream from cAMP production and possibly is mediated by direct interference with gene transcription (Schwaninger et al., 1995) . Unlike cyclosporin A, FK-506 does not bind to cyclophilin receptors but instead selectively binds to the FK-506 binding protein (Marks, 1996) . Rapamycin, an antagonist of FK-506 (Sabatini et al., 1994) , blocked the inhibitory effect of FK-506 but not of cyclosporin A on APP overexpression stimulated by PGE 2 , without producing significant changes in basal APP levels. These data suggest that inhibition of calcineurin by cyclosporin A or FK-506 (Steiner et al., 1997) may underlie the inhibitory effect of these immunosuppressants on APP synthesis stimulated by PGE 2 or elevations in cAMP production. Okadaic acid (1 M), another phosphatase inhibitor, did not suppress APP overexpression stimulated by PGE 2 but instead caused astrocytes to detach from the culture dishes, suggesting that okadaic acid may induce toxicity (our unpublished data).
Treatment with PGE 2 also increased the levels of GFAP in our cultured astrocytes (this study) and decreased the levels of ␤-actin mRNA (Lee et al., 1997b) , suggesting that these cultured astrocytes resemble reactive astrocytes. GFAP-positive reactive astrocytes exhibited rapid and persistent increases in APP immunoreactivity after brain lesions or ischemia (Siman et al., 1989; Banati et al., 1996) . Although the phagocytic activity of astrocytes or microglia can increase APP immunoreactivity (Paresce et al., 1996) , our study suggests that GFAP-positive astrocytes can actively upregulate APP synthesis after brain injury. The loss of synapses appears to be an early event in the pathology of AD and is related to the extent of reactive astrogliosis (Brun et al., 1995; Heinonen et al., 1995) . The invasion and proliferation of reactive astrocytes within degenerating regions may explain the increased levels of GFAP in the brains and cerebrospinal fluid of AD patients (Wallin et al., 1996) . Indeed, the proliferation of astrocytes associated with neurodegeneration in the frontal cortex and hippocampus of AD brains can cause an upregulation of ␤-adrenergic receptors (Kalaria et al., 1989) . Increased circulating levels of norepinephrine after brain injury (Hodges-Savola et al., 1996) may result in the aberrant activation of ␤-adrenergic receptors coupled to cAM P signaling to stimulate APP overexpression in astrocytes (Lee et al., 1997b) . These studies, together with our present finding that activation of PGE 2 receptors can stimulate APP synthesis, underscore the contribution of receptor activation in the overproduction of APP.
APP overexpression in cultured astrocytes treated with PGE 2 was associated with increased secretion of APP holoprotein. Although secreted APP is usually truncated at the C terminus, antisera C8 that is directed at the C terminus of APP (Selkoe et al., 1988) detected increased amounts of APP holoprotein (ϳ130 kDa) in the media of astrocytes treated with PGE 2 for 24 hr. Similarly, Chinese hamster ovary cells overexpressing APP751 also exhibited increased secretion of APP holoprotein (Efthimiopoulos et al., 1996) . APP holoprotein is found in human cerebrospinal fluid and can be actively released from secretory vesicles in response to receptor stimulation or neuronal depolarization (Efthimiopoulos et al., 1996) . It is not known whether secreted APP holoprotein is reinternalized for subsequent processing or whether it can be metabolized in the extracellular space.
Neuronal damage or amyloid deposits in AD may trigger inflammatory or immune processes and accelerate neuropathology. Epidemiological data suggest that such anti-inflammatory therapies such as nonsteroidal anti-inflammatory drugs or dapsone may be effective in slowing the progression of neuropathology in AD (McGeer and McGeer, 1995) . Increased lipid peroxidation and formation of prostaglandins have been detected in AD (Iwamoto et al., 1989; Subbarao et al., 1990) .
Our findings show that PGE 2 can stimulate GFAP expression, APP synthesis, and the secretion of amyloidogenic APP holoprotein from cultured astrocytes. APP overexpression in cell cultures and in transgenic mice is associated with disorders of the CNS and the production of neurotoxic or amyloidogenic APP fragments (Yoshikawa et al., 1992; Cordell, 1994; Hsiao et al., 1995) . We suggest that anti-inflammatory agents (e.g., aspirin or indomethacin), inhibitors of PL A 2 (e.g., dexamethasone), or inhibitors of prostaglandin synthase (cyclooxygenase) may prevent the neuropathologies associated with APP overexpression.
